EnteroTrack and Denver-based University of Colorado have entered into an exclusive license agreement that will allow EnteroTrack to develop and market a device that monitors gastrointestinal tract inflammation.
The device is a capsule that allows for analysis of esophageal content. The capsule can help identify the presence of esophageal inflammation and can also be used to monitor the effectiveness of treatment.
"Given the increasing pressures to contain costs, there is clear rationale for innovative, cost-effective methods to monitor esophageal diseases," said Robin Shandas, PhD, professor and chair of bioengineering at the University of Colorado Denver and interim CEO of EnteroTrack. "This technology holds particular promise because it can reduce total patient care costs while keeping good margins. We hope to obtain FDA approval for the device in 2015."
More articles on GI/endoscopy:
Boston Scientific discloses insider trading activity
Otto Kaiser Memorial's $43.8M replacement facility to include endoscopy suite
Salix Pharmaceuticals CEO Carolyn Logan to retire